Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
Natasha Ann Pereira, Kah Fai Chan, Pao Chun Lin, et al.
mAbs (2018) Vol. 10, Iss. 5, pp. 693-711
Open Access | Times Cited: 281

Showing 1-25 of 281 citing articles:

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Juliana T. W. Tong, Paul W. R. Harris, Margaret A. Brimble, et al.
Molecules (2021) Vol. 26, Iss. 19, pp. 5847-5847
Open Access | Times Cited: 230
The history of IgG glycosylation and where we are now
Brian A. Cobb
Glycobiology (2019) Vol. 30, Iss. 4, pp. 202-213
Open Access | Times Cited: 155
FcγR Binding and ADCC Activity of Human IgG Allotypes
Steven W. de Taeye, Arthur E. H. Bentlage, Mirjam M. Mebius, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 144
Advances in antibody-based therapy in oncology
Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nature Cancer (2023) Vol. 4, Iss. 2, pp. 165-180
Closed Access | Times Cited: 119
Therapeutic targeting of regulatory T cells in cancer
Feng Shan, Ashwin Somasundaram, Tullia C. Bruno, et al.
Trends in cancer (2022) Vol. 8, Iss. 11, pp. 944-961
Open Access | Times Cited: 115
FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer
Kayla Bastian, Emma Scott, David J. Elliott, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 1, pp. 455-455
Open Access | Times Cited: 114
The global landscape of approved antibody therapies
Xiaochen Lyu, Qichao Zhao, Julia Hui, et al.
Antibody Therapeutics (2022) Vol. 5, Iss. 4, pp. 233-257
Open Access | Times Cited: 99
Role of Fcγ receptors in HER2-targeted breast cancer therapy
Antonino Musolino, William J. Gradishar, Hope S. Rugo, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003171-e003171
Open Access | Times Cited: 91
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 65
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial
Zev A. Wainberg, Yoon‐Koo Kang, Keun‐Wook Lee, et al.
Gastric Cancer (2024) Vol. 27, Iss. 3, pp. 558-570
Open Access | Times Cited: 21
The Ligands for Human IgG and Their Effector Functions
Steven W. de Taeye, Theo Rispens, Gestur Vidarsson
Antibodies (2019) Vol. 8, Iss. 2, pp. 30-30
Open Access | Times Cited: 135
Antibody Conjugates-Recent Advances and Future Innovations
Donmienne Leung, Jacqueline Wurst, Tao Liu, et al.
Antibodies (2020) Vol. 9, Iss. 1, pp. 2-2
Open Access | Times Cited: 103
Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance
Charita Furumaya, Paula Martínez-Sanz, Panagiota Bouti, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 83
Genetic glycoengineering in mammalian cells
Yoshiki Narimatsu, Christian Büll, Yen‐Hsi Chen, et al.
Journal of Biological Chemistry (2021) Vol. 296, pp. 100448-100448
Open Access | Times Cited: 74
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
Lucia Lisi, Pedro Miguel Lacal, Maria Martire, et al.
Pharmacological Research (2021) Vol. 175, pp. 105997-105997
Closed Access | Times Cited: 68
Sialylation as an Important Regulator of Antibody Function
Ravi Vattepu, Sunny L. Sneed, Robert M. Anthony
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 55
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Natalia Sauer, Wojciech Szlasa, Laura Jonderko, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9958-9958
Open Access | Times Cited: 52
Glycobiology of rheumatic diseases
Theresa Kissel, René E. M. Toes, T. Huizinga, et al.
Nature Reviews Rheumatology (2022) Vol. 19, Iss. 1, pp. 28-43
Open Access | Times Cited: 52
Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
Josée Golay, Alain E. Andrea, Irene Cattaneo
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 51
Strategies for Glycoengineering Therapeutic Proteins
Kris Dammen‐Brower, Paige Epler, Stanley Zhu, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 41
Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models
Guanjie Li, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Medicine (2023) Vol. 51, Iss. 2
Open Access | Times Cited: 35
Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
Minchuan Zhang, Kong‐Peng Lam, Shengli Xu
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Frances Rocamora, Angelo G. Peralta, Seunghyeon Shin, et al.
Biotechnology Advances (2023) Vol. 67, pp. 108206-108206
Open Access | Times Cited: 22
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 11
An update on colorectal cancer microenvironment, epigenetic and immunotherapy
Ketao Jin, Chengcheng Ren, Yuyao Liu, et al.
International Immunopharmacology (2020) Vol. 89, pp. 107041-107041
Closed Access | Times Cited: 69
Page 1 - Next Page

Scroll to top